Bottom line
IHE vs XPH: the short answer
IHE (iShares U.S. Pharmaceuticals ETF) and XPH (State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF) are quite different portfolios: only about 17% of their top holdings (by weight) are shared.
XPH is cheaper at 0.35% vs 0.37% — a difference of $2.00 a year per $10,000 invested.
Over five years, IHE returned +9.1% a year vs +2.8% for XPH.
Updated Nov 19, 2026
IHE vs XPH side by side
| IHE | XPH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.37% | 0.35% |
| Annual cost per $10k | $37 | $35 |
| 10-yr cost on $10k (prospectus) | $468 | $443 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +31.7% | +31.6% |
| 5-yr return (annualized) | +9.1% | +2.8% |
| 10-yr return (annualized) | +6.2% | +1.9% |
| Best quarter | +17.6% | +28.6% |
| Worst quarter | −16.0% | −24.3% |
| Net assets (fund) | $1.1B | $428.4M |
| Number of holdings | 59 | 67 |
| Portfolio turnover | 29% | 69% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IHE | XPH | Difference |
|---|---|---|---|
| 2025 | +31.7% | +31.6% | +0.1% |
| 2024 | +8.1% | +5.1% | +3.0% |
| 2023 | +1.0% | +2.9% | −1.9% |
| 2022 | −4.8% | −9.8% | +5.0% |
| 2021 | +12.8% | −10.5% | +23.3% |
| 2020 | +13.8% | +14.4% | −0.6% |
| 2019 | +15.5% | +25.7% | −10.2% |
| 2018 | −7.7% | −15.2% | +7.5% |
| 2017 | +10.7% | +12.0% | −1.4% |
| 2016 | −11.7% | −23.2% | +11.5% |
Source: Fund prospectus bar charts
Holdings overlap
12 of IHE's top 25 holdings also appear in XPH's top 25.
| Holding | IHE | XPH |
|---|---|---|
| Merck & Co., Inc. | 4.55% | 1.65% |
| Elanco Animal Health Incorporated | 2.81% | 1.64% |
| Corcept Therapeutics Incorporated | 1.90% | 1.70% |
| Ligand Pharmaceuticals Incorporated | 1.45% | 1.94% |
| Definium Therapeutics Inc | 1.39% | 3.09% |
| Liquidia Corp | 1.28% | 1.86% |
| Indivior Pharmaceuticals, Inc. | 1.14% | 1.64% |
| Crinetics Pharmaceuticals Inc | 0.90% | 1.66% |
| Edgewise Therapeutics Inc | 0.70% | 1.88% |
| Amneal Pharmaceuticals, Inc. | 0.68% | 1.72% |
| Enliven Therapeutics Inc | 0.63% | 2.09% |
| Veradermics Inc | 0.56% | 2.02% |
Source: SEC Form N-PORT
IHE top 10
- Johnson & Johnson — 22.44%
- Eli Lilly And Company — 22.25%
- BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares — 6.24%
- Merck & Co., Inc. — 4.55%
- Bristol-myers Squibb Company — 4.37%
- Royalty Pharma Plc — 4.34%
- Viatris Inc. — 4.22%
- Pfizer Inc. — 3.96%
- Zoetis Inc. — 3.73%
- Jazz Pharmaceuticals Public Limited Company — 3.45%
XPH top 10
- State Street Global Advisors — 8.58%
- Definium Therapeutics Inc — 3.09%
- MBX Biosciences Inc — 2.72%
- Alumis Inc — 2.14%
- AtaiBeckley Inc — 2.13%
- Trevi Therapeutics Inc — 2.12%
- Enliven Therapeutics Inc — 2.09%
- Amylyx Pharmaceuticals Inc — 2.04%
- VeraDermics Inc — 2.02%
- Ligand Pharmaceuticals Inc — 1.94%
FAQ
What is the difference between IHE and XPH?
Which is cheaper, IHE or XPH?
Should I own both IHE and XPH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.